{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T12:44:42Z","timestamp":1771073082943,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005725","name":"CHDI Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fund for Scientific Research Flanders"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00259-022-05945-z","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T10:05:49Z","timestamp":1661335549000},"page":"48-60","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Biodistribution and dosimetry in human healthy volunteers of the PET radioligands [11C]CHDI-00485180-R and [11C]CHDI-00485626, designed for quantification of cerebral aggregated mutant huntingtin"],"prefix":"10.1007","volume":"50","author":[{"given":"Aline","family":"Delva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Koole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Serdons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Bormans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longbin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Bard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod","family":"Khetarpal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celia","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Munoz-Sanjuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mette","family":"Skinbjerg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wim","family":"Vandenberghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5200-7245","authenticated-orcid":false,"given":"Koen","family":"Van Laere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"5945_CR1","doi-asserted-by":"publisher","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","volume":"1","author":"GP Bates","year":"2015","unstructured":"Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, et al. Huntington disease Nat Rev Dis Primers. 2015;1:15005. https:\/\/doi.org\/10.1038\/nrdp.2015.5.","journal-title":"Huntington disease Nat Rev Dis Primers"},{"key":"5945_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28855","author":"JJ Ferreira","year":"2021","unstructured":"Ferreira JJ, Rodrigues FB, Duarte GS, Mestre TA, Bachoud-Levi AC, Bentivoglio AR, et al. A MDS evidence-based review on treatments for Huntington\u2019s disease. Mov Disord. 2021. https:\/\/doi.org\/10.1002\/mds.28855.","journal-title":"Mov Disord"},{"key":"5945_CR3","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.neuron.2019.05.001","volume":"102","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi SJ, Ghosh R, Leavitt BR. Huntingtin lowering strategies for disease modification in Huntington\u2019s disease. Neuron. 2019;102:899. https:\/\/doi.org\/10.1016\/j.neuron.2019.05.001.","journal-title":"Neuron"},{"key":"5945_CR4","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1172\/JCI80743","volume":"125","author":"EJ Wild","year":"2015","unstructured":"Wild EJ, Boggio R, Langbehn D, Robertson N, Haider S, Miller JR, et al. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients. J Clin Invest. 2015;125:1979\u201386. https:\/\/doi.org\/10.1172\/JCI80743.","journal-title":"J Clin Invest"},{"key":"5945_CR5","doi-asserted-by":"publisher","first-page":"8608","DOI":"10.1021\/acs.jmedchem.0c00955","volume":"63","author":"L Liu","year":"2020","unstructured":"Liu L, Prime ME, Lee MR, Khetarpal V, Brown CJ, Johnson PD, et al. Imaging mutant huntingtin aggregates: development of a potential PET ligand. J Med Chem. 2020;63:8608\u201333. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00955.","journal-title":"J Med Chem"},{"key":"5945_CR6","doi-asserted-by":"publisher","first-page":"12003","DOI":"10.1021\/acs.jmedchem.1c00667","volume":"64","author":"L Liu","year":"2021","unstructured":"Liu L, Johnson PD, Prime ME, Khetarpal V, Lee MR, Brown CJ, et al. [(11)C]CHDI-626, a PET tracer candidate for imaging mutant huntingtin aggregates with reduced binding to AD pathological proteins. J Med Chem. 2021;64:12003\u201321. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00667.","journal-title":"J Med Chem"},{"key":"5945_CR7","doi-asserted-by":"publisher","first-page":"17977","DOI":"10.1038\/s41598-021-97334-z","volume":"11","author":"F Herrmann","year":"2021","unstructured":"Herrmann F, Hessmann M, Schaertl S, Berg-Rosseburg K, Brown CJ, Bursow G, et al. Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates. Sci Rep. 2021;11:17977. https:\/\/doi.org\/10.1038\/s41598-021-97334-z.","journal-title":"Sci Rep"},{"key":"5945_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05578-8","author":"D Bertoglio","year":"2021","unstructured":"Bertoglio D, Verhaeghe J, Miranda A, Wyffels L, Stroobants S, Mrzljak L, et al. Longitudinal preclinical evaluation of the novel radioligand [11C]CHDI-626 for PET imaging of mutant huntingtin aggregates in Huntington\u2019s disease. Eur J Nucl Med Mol Imaging. 2021. https:\/\/doi.org\/10.1007\/s00259-021-05578-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5945_CR9","doi-asserted-by":"crossref","unstructured":"Bertoglio D, Bard J, Hessmann M, Liu L, G\u00e4rtner A, De Lombaerde S, et al. Development of a ligand for in vivo imaging mutant huntingtin in Huntington\u2019s disease. Sci Transl Med. 2022.","DOI":"10.1126\/scitranslmed.abm3682"},{"key":"5945_CR10","doi-asserted-by":"publisher","unstructured":"Stabin MG, Siegel JA. RADAR dose estimate report: a compendium of radiopharmaceutical dose estimates based on OLINDA\/EXM version 2.0. J Nucl Med. 2018;59:154\u201360. https:\/\/doi.org\/10.2967\/jnumed.117.196261.","DOI":"10.2967\/jnumed.117.196261"},{"key":"5945_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.2967\/jnumed.120.257402","volume":"62","author":"P Zanotti-Fregonara","year":"2021","unstructured":"Zanotti-Fregonara P, Lammertsma AA, Innis RB. (11)C dosimetry scans should be abandoned. J Nucl Med. 2021;62:158\u20139. https:\/\/doi.org\/10.2967\/jnumed.120.257402.","journal-title":"J Nucl Med"},{"key":"5945_CR12","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s00259-011-2005-8","volume":"39","author":"P Zanotti-Fregonara","year":"2012","unstructured":"Zanotti-Fregonara P, Innis RB. Suggested pathway to assess radiation safety of 11C-labeled PET tracers for first-in-human studies. Eur J Nucl Med Mol Imaging. 2012;39:544\u20137. https:\/\/doi.org\/10.1007\/s00259-011-2005-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5945_CR13","unstructured":"Radiation protection 99: Guidance on medical exposures in medical and biomedical research [cited 9\/07\/2021]. Available from: https:\/\/ec.europa.eu\/energy\/sites\/ener\/files\/documents\/099_en.pdf.; 1998."},{"key":"5945_CR14","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2967\/jnumed.116.176628","volume":"58","author":"G Leurquin-Sterk","year":"2017","unstructured":"Leurquin-Sterk G, Celen S, Van Laere K, Koole M, Bormans G, Langlois X, et al. What we observe in vivo is not always what we see in vitro: development and validation of 11C-JNJ-42491293, a novel radioligand for mGluR2. J Nucl Med. 2017;58:110\u20136. https:\/\/doi.org\/10.2967\/jnumed.116.176628.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05945-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-022-05945-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05945-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T12:05:07Z","timestamp":1668600307000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-022-05945-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["5945"],"URL":"https:\/\/doi.org\/10.1007\/s00259-022-05945-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]},"assertion":[{"value":"8 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study has been approved by the institutional review board (University hospitals and KU Leuven Ethics Committee) and performed in accordance with the World Medical Association Declaration of Helsinki. Written informed consent was obtained from all the participants before study inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"AD is a PhD fellow of the Fund for Scientific Research Flanders (FWO). KVL and WV are Senior Clinical Investigators of the FWO. MK has no financial interests. JB, LL, AW, VK, YW, MS, CD, and IM-S are employed by CHDI Management, Inc. as advisors to CHDI Foundation, Inc. The radioligands have been provided by CHDI, USA, and the human imaging study has been performed in Leuven, Belgium, under contract between CHDI and KU Leuven. The following granted patent is related to this work: Probes for Imaging Huntingtin Proteins, International Publication Number WO 2016\/033445 Al (published on 3 March 2016 with filing number #PCT\/US2015\/047407) for [<sup>11<\/sup>C]CHDI-180R, and WO 2017\/040336 A1 (published on 9 March 2017 with filing number #PCT\/US2016\/049112) for [<sup>11<\/sup>C]CHDI-626.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}